{"id":"vfend-voriconazole-tablet","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Visual disturbances (blurred vision, photopsia)"},{"rate":"10-20","effect":"Hepatotoxicity (elevated liver enzymes)"},{"rate":"5-10","effect":"Rash"},{"rate":"5-10","effect":"Photosensitivity"},{"rate":"5-10","effect":"Headache"},{"rate":"1-5","effect":"Hallucinations"},{"rate":"1-5","effect":"QT prolongation"}]},"_chembl":{"chemblId":"CHEMBL638","moleculeType":"Small molecule","molecularWeight":"349.32"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking a key enzyme in the ergosterol biosynthesis pathway, voriconazole causes depletion of ergosterol and accumulation of toxic sterol precursors, leading to fungal cell membrane instability and cell death. This mechanism is selective for fungi because the target enzyme and ergosterol-dependent membrane structure are unique to fungal cells, making it effective against a broad spectrum of fungal pathogens.","oneSentence":"Voriconazole inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:15:10.906Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Invasive aspergillosis"},{"name":"Esophageal candidiasis"},{"name":"Candidemia in non-neutropenic patients"},{"name":"Serious Candida infections of the skin and infections of the abdomen, kidney, bladder wall, and wounds"},{"name":"Scedosporium apiorum and Fusarium species infections in immunocompromised patients"}]},"trialDetails":[{"nctId":"NCT07457203","phase":"PHASE1","title":"Study on the Drug Interaction Between Buagafuran and Voriconazole","status":"NOT_YET_RECRUITING","sponsor":"Beijing Union Pharmaceutical Factory Ltd","startDate":"2026-04","conditions":"Drug Drug Interaction (DDI)","enrollment":18},{"nctId":"NCT07426042","phase":"PHASE1","title":"Effect of Dexamethasone on CYP Enzyme Activity in Healthy Male Subjects","status":"NOT_YET_RECRUITING","sponsor":"Min Kyu Park","startDate":"2026-04","conditions":"Drug-Drug Interactions","enrollment":12},{"nctId":"NCT07215273","phase":"PHASE2","title":"Study of EL219 vs Standard of Care for Early Antifungal Therapy of Suspected Invasive Mould Infections","status":"RECRUITING","sponsor":"Elion Therapeutics, Inc.","startDate":"2026-02","conditions":"Suspected Invasive Mould Infection","enrollment":80},{"nctId":"NCT05822544","phase":"PHASE1","title":"Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes","status":"RECRUITING","sponsor":"OrsoBio, Inc","startDate":"2023-04-22","conditions":"Healthy Subjects, Obesity, Type 2 Diabetes","enrollment":564},{"nctId":"NCT03013998","phase":"PHASE1, PHASE2","title":"Study of Biomarker-Based Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Beat AML, LLC","startDate":"2016-11","conditions":"Previously Untreated Relapsed Refractory Acute Myeloid Leukemia","enrollment":3000},{"nctId":"NCT04865419","phase":"PHASE1","title":"Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2021-06-11","conditions":"Haematological Malignancies","enrollment":46},{"nctId":"NCT02014558","phase":"PHASE1, PHASE2","title":"Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2013-10-09","conditions":"Acute Myeloid Leukemia","enrollment":265},{"nctId":"NCT03672292","phase":"PHASE2","title":"Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis","status":"TERMINATED","sponsor":"Scynexis, Inc.","startDate":"2019-01-22","conditions":"Invasive Pulmonary Aspergillosis","enrollment":22},{"nctId":"NCT01782131","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-09-25","conditions":"Fungal Infections, Invasive Pulmonary Aspergillosis","enrollment":585},{"nctId":"NCT06044558","phase":"","title":"Effect of Azole/Echinocandin Use on Tacrolimus Pharmacokinetics","status":"COMPLETED","sponsor":"LI YAN","startDate":"2022-09-01","conditions":"Kidney Transplant Patients","enrollment":507},{"nctId":"NCT05264142","phase":"PHASE1","title":"Risk of CYP2C19 Phenoconversion in Healthy Volunteers With Rapid, Normal, and Intermediate Predicted Metabolizers' Status","status":"UNKNOWN","sponsor":"University Hospital, Geneva","startDate":"2022-04-01","conditions":"Healthy","enrollment":45},{"nctId":"NCT05380245","phase":"PHASE4","title":"Drug-Drug Interaction Study of Voriconazole With Clarithromycin.","status":"COMPLETED","sponsor":"Abdul Wali Khan University Mardan","startDate":"2018-11-01","conditions":"Healthy","enrollment":12},{"nctId":"NCT04229303","phase":"PHASE1","title":"Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2020-02-11","conditions":"Allergic Bronchopulmonary Aspergillosis","enrollment":58},{"nctId":"NCT04966234","phase":"PHASE2, PHASE3","title":"A New Posaconazole Dosing Regimen for Paediatric Patients With Cystic Fibrosis and Aspergillus Infection","status":"UNKNOWN","sponsor":"Bambino Gesù Hospital and Research Institute","startDate":"2021-04-22","conditions":"Cystic Fibrosis, Aspergillosis","enrollment":135},{"nctId":"NCT03471988","phase":"PHASE3","title":"Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep Mycosis","status":"COMPLETED","sponsor":"Asahi Kasei Pharma Corporation","startDate":"2018-04-16","conditions":"Deep Mycosis","enrollment":103},{"nctId":"NCT02180165","phase":"PHASE3","title":"Assessing the Safety and Efficacy of MK-5592 (Posaconazole) in Japanese Participants With Fungal Infection (MK-5592-101)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-07-29","conditions":"Aspergillosis","enrollment":116},{"nctId":"NCT04145583","phase":"PHASE1","title":"A Study Evaluating Drug-Drug Interaction (DDI) Between HSK3486 Injectable Emulsion and Voriconazole Tablets","status":"COMPLETED","sponsor":"Sichuan Haisco Pharmaceutical Group Co., Ltd","startDate":"2019-12-14","conditions":"Anesthesia, Sedation","enrollment":16},{"nctId":"NCT02283905","phase":"PHASE4","title":"Amphotericin-B and Voriconazole for Pulmonary Blastomycosis","status":"TERMINATED","sponsor":"University of Manitoba","startDate":"2015-06","conditions":"Blastomycosis","enrollment":2},{"nctId":"NCT02576366","phase":"PHASE4","title":"Phenotypic Drug Probes as Predictors of Drug-drug Interactions With Tacrolimus","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2016-06","conditions":"Drug Interactions, Kidney Transplantation","enrollment":24},{"nctId":"NCT00997035","phase":"PHASE3","title":"The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2010-05","conditions":"Corneal Ulcer, Eye Infections, Fungal","enrollment":240},{"nctId":"NCT03760276","phase":"PHASE1","title":"A Study to Evaluate the Appropriateness of the Voriconazole Dosing Regimen","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2018-08-20","conditions":"Fungal Infection","enrollment":11},{"nctId":"NCT02906176","phase":"PHASE1","title":"Influence of SLCO2B1 Polymorphism on the PK of Voriconazole in CYP2C19 PM","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2016-09","conditions":"Healthy Volunteers","enrollment":12},{"nctId":"NCT02381080","phase":"PHASE1","title":"Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-05-19","conditions":"B-Cell Chronic Lymphocytic Leukemia","enrollment":26},{"nctId":"NCT00836875","phase":"PHASE3","title":"A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children","status":"TERMINATED","sponsor":"Pfizer","startDate":"2009-05","conditions":"Invasive Aspergillosis","enrollment":31},{"nctId":"NCT02396225","phase":"NA","title":"Concentrations of Voriconazole in Blood and BAL-fluid After Inhalation and Oral Administration","status":"TERMINATED","sponsor":"University of Aarhus","startDate":"2015-03","conditions":"Invasive Aspergillosis","enrollment":12},{"nctId":"NCT01787032","phase":"PHASE1","title":"Drug-drug Interaction Trial of BI 113608 in Combination With Ketoconazole and Voriconazole in Healthy Male Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-01","conditions":"Healthy","enrollment":20},{"nctId":"NCT02912156","phase":"PHASE4","title":"Pharmacokinetics of Two Different Formulation of Voriconazole","status":"COMPLETED","sponsor":"Yung Shin Pharm. Ind. Co., Ltd.","startDate":"2016-06","conditions":"Fungus Infection","enrollment":29},{"nctId":"NCT00556998","phase":"PHASE2","title":"A Multiple-Dose Study To Evaluate The Pharmacokinetics And Safety Of Voriconazole In Immunocompromised Adolescents","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-06","conditions":"Pharmacokinetics","enrollment":26},{"nctId":"NCT02100761","phase":"","title":"CYP 2C19 Polymorphism and Voriconazole Trough Concentration in Chinese Adult Patients","status":"UNKNOWN","sponsor":"dingshifang","startDate":"2014-06","conditions":"Invasive Pulmonary Aspergillosis","enrollment":200},{"nctId":"NCT01660334","phase":"","title":"Voriconazole (Vfend) Special Investigation (Regulatory Post Marketing Commitment Plan)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-07","conditions":"Scedosporium Infection","enrollment":13},{"nctId":"NCT01151085","phase":"","title":"Voriconazole (Vfend) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-04","conditions":"Systemic Mycosis","enrollment":1002},{"nctId":"NCT00833482","phase":"PHASE1","title":"Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-09","conditions":"Human Immunodeficiency Virus Type 1 (HIV-1), HIV Infections","enrollment":185},{"nctId":"NCT01073631","phase":"","title":"Non-Interventional Post Marketing Surveillance Study To Observe The Safety And Efficacy Of Vfend® Tablet In Korea","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-03","conditions":"Serious Fungal Infections","enrollment":543},{"nctId":"NCT00647907","phase":"PHASE4","title":"A Study of the Efficacy and Safety of Voriconazole for the Treatment of Fungal Infections","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-04","conditions":"Candidiasis, Cryptococcosis, Aspergillosis","enrollment":7},{"nctId":"NCT00855101","phase":"PHASE1","title":"A Pharmacokinetic And Safety Study Of Voriconazole In Healthy Male And Female Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-04","conditions":"Healthy Volunteers","enrollment":35}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"LIVER DISORDER"},{"count":1,"reaction":"ABDOMINAL PAIN UPPER"},{"count":1,"reaction":"ALANINE AMINOTRANSFERASE INCREASED"},{"count":1,"reaction":"ANAEMIA"},{"count":1,"reaction":"ASPARTATE AMINOTRANSFERASE INCREASED"},{"count":1,"reaction":"BK VIRUS INFECTION"},{"count":1,"reaction":"BRONCHOPULMONARY ASPERGILLOSIS"},{"count":1,"reaction":"CEREBRAL ASPERGILLOSIS"},{"count":1,"reaction":"CHRONIC GRAFT VERSUS HOST DISEASE"},{"count":1,"reaction":"CONVULSION"}],"_approvalHistory":[],"publicationCount":29,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Oral"],"phase":"marketed","status":"active","brandName":"Vfend (voriconazole) tablet","genericName":"Vfend (voriconazole) tablet","companyName":"Seoul National University Hospital","companyId":"seoul-national-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Voriconazole inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane. Used for Invasive aspergillosis, Esophageal candidiasis, Candidemia in non-neutropenic patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":33,"withResults":4},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}